Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 13;8(4):679.
doi: 10.3390/vaccines8040679.

Anti-Influenza Effect of Nanosilver in a Mouse Model

Affiliations

Anti-Influenza Effect of Nanosilver in a Mouse Model

Irina V Kiseleva et al. Vaccines (Basel). .

Abstract

The present study assesses copper metabolism of the host organism as a target of antiviral strategy, basing on the "virocell" concept. Silver nanoparticles (AgNPs) were used as a specific active agent because they reduce the level of holo-ceruloplasmin, the main extracellular cuproenzyme. The mouse model of influenza virus A infection was used with two doses: 1 LD50 and 10 LD50. Three treatment regimens were used: Scheme 1-mice were pretreated 4 days before infection and then every day during infection development; Scheme 2-mice were pretreated four days before infection and on the day of virus infection; Scheme 3-virus infection and AgNP treatment started simultaneously, and mice were injected with AgNPs until the end of the experiment. The mice treated by Scheme 1 demonstrated significantly lower mortality, the protection index reached 60-70% at the end of the experiment, and mean lifespan was prolonged. In addition, the treatment of the animals with AgNPs resulted in normalization of the weight dynamics. Despite the amelioration of the infection, AgNP treatment did not influence influenza virus replication. The possibility of using nanosilver as an effective indirectly-acting antiviral drug is discussed.

Keywords: ceruloplasmin; copper status; indirectly-acting antiviral drug; influenza; influenza virus replication; prophylaxis and treatment; silver nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Schedules of treatment of mice with silver nanoparticles (AgNPs). Red arrow—intraperitoneal administration of AgNPs. Blue arrow—inoculation of the virus.
Figure 2
Figure 2
Test groups of mice.
Figure 3
Figure 3
The percentage of lung area affected in mice inoculated with A/South Africa/3626/2013 (H1N1) pdm09 (SA).
Figure 4
Figure 4
The physical properties of fabricated AgNPs: UV/Vis spectrum (A) and transmission electron microscopy image (B).
Figure 5
Figure 5
Oxidase activity of blood serum of mice against the background of influenza infection. (AC)—mice were treated with AgNPs according to Schemes 1–3, correspondingly. Abscissa, mice groups: 1—without treatment; 2—treatment with AgNPs for 4 days; 3—treatment with AgNPs for 7 days; 4—infected with 1 LD50; 5—treatment with AgNPs + 1 LD50; 6—infected with 10 LD50; 7—treatment with AgNPs + 10 LD50.
Figure 6
Figure 6
Protection of mice from lethal primary viral pneumonia by AgNPs. Mean weight loss ± SEM (p < 0.05) (A,C) and survival, % ± SE (p < 0.05) (B,D), were monitored daily for 14 days. Mice were inoculated intranasally with 1 LD50 (A,B) or 10 LD50 (C,D).
Figure 7
Figure 7
Virus replication in the lungs of mice on D3 post-infection with 10−2, 10−1, 1, and 10 LD50 as measured by titration in chicken embryos (mean ± SD, p > 0.05). Mice were infected with the dose of (A) 10−2 LD50; (B) 10−1 LD50; (C) 1 LD50; and (D) 10 LD50; red circles—virus titer in lung tissue of control mice; blue circles—virus titer in lung tissue of mice treated by AgNPs according to Scheme 1; gray—the limit of virus detection (1.9 log10 EID50/mL/g).
Figure 8
Figure 8
Target-dependent types of anti-influenza virus compounds.

References

    1. CDC Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2019–2020 Influenza Season. [(accessed on 5 October 2020)]; Available online: https://www.cdc.gov/mmwr/volumes/68/rr/rr6803a1.htm.
    1. NVAC Strategies to achieve the healthy people 2020 annual influenza vaccine coverage goal for health-care personnel: Recommendations from the National Vaccine Advisory Committee. Public Health Rep. 2013;128:7–25. doi: 10.1177/003335491312800103. - DOI - PMC - PubMed
    1. WHO Influenza Vaccines. [(accessed on 23 October 2020)]; Available online: https://www.who.int/influenza/vaccines/en/
    1. Mameli C., Cocchi I., Fumagalli M., Zuccotti G. Influenza vaccination: Effectiveness, indications, and limits in the pediatric population. Front. Pediatr. 2019;7:317. doi: 10.3389/fped.2019.00317. - DOI - PMC - PubMed
    1. Shie J.J., Fang J.M. Development of effective anti-influenza drugs: Congeners and conjugates—A review. J. Biomed Sci. 2019;26:84. doi: 10.1186/s12929-019-0567-0. - DOI - PMC - PubMed